Hybrid eventIn-person & virtual
March 15–17, 2027Singapore · Village Hotel Changi

Talk Details · IOC 2027

Effectiveness of the ranibizumab biosimilar OngaviaA® in treating patients with neovascular age-related macular degeneration in a district general hospital in North Wales, United Kingdom

Oral · In-Person · Day 1

Abstract

About this talk

Introduction: The degenerative eye condition, age-related macular degeneration (ARMD), is the leading cause of serious vision loss in older adults. In wet AMD, intravitreal injection of Anti Vascular Endothelial Growth Factor (anti-VEGFs) is the accepted practice. Ongavia®is an anti-VEGFs agent which is a biosimilar of Ranibizumab. Research is needed to determine Ongavia®'s long-term efficacy and safety in real-life studies. Therefore, this study was conducted to determine the effectiveness of Ongavia® in patients with neovascular age-related macular degeneration (nARMD) in a District General Hospital in North Wales, United Kingdom.

Methods: This was a retrospective cross-sectional analytical study carried out among 64 patients who received Ongavia® and 76 patients who received Lucentis, presenting to the Eye Clinic, with nAMD. Pre-designed data extraction sheet was used to record data from the patient records and prospective follow up data were collected. Descriptive statistics (frequency, percentages, mean, standard deviation), paired t-test, independent sample t-test and chi-square test were used to present data.

Results: The study included 64 nARMD patients treated with Ongavia®, with an average age of 81.6 years and 60.9% females. The majority of individuals improved their visual acuity and central foveal thickness after Ongavia® treatment, which stabilised with repeated dosages. There were significant improvements in visual acuity, central foveal thickness, macular cube volume and average macular cube thickness. The RPE offset area and volume improved during the loading doses but fluctuated afterwards. Ongavia® did not significantly impact geographic atrophy as there was no obvious association noted with sub-RPE illumination area. Ganglion cell layer thickness remained stable throughout the study period. There was no statistically significant difference in results between Ongavia® and Ranibizumab at the end of the follow-up period of 28 weeks.

Conclusions and recommendations: Ongavia® therapy dramatically improved visual acuity, central foveal thickness, macular cube volume, and average macular cube thickness, with the effects lasting throughout treatment. Ongavia® developed as a cost-effective option with steady results during the loading phase, equivalent to Lucentis. Recommendations emphasise personalised treatment programs, frequent monitoring of retinal fluid, and long-term studies to assess durability, while emphasising the medications' similar safety and efficacy profiles to boost patient trust and compliance.

Speaker

About the speaker

Jai Shankar

Jai Shankar

Wrexham Maelor Hospital, United Kingdom

View full speaker profile →

Join the IOC 2027 delegation

Singapore · March 15–17, 2027· Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.